Investigational drug · Phase 3
DAS181
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
15
Any phase or sponsor naming "DAS181"
First trial start
2019
May 23, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DAS181", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lower Respiratory Tract Infection
- Parainfluenza
- Immunocompromised
- COVID-19
Approved drugs for the same conditions: COVID-19 · Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "DAS181" as an intervention, largest first.
- Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired InfluenzaPivotal-lookingCompleted
Ansun Biopharma, Inc.Industry
NCT01740063 · 423 participants · Start Nov 2012 · Primary completion Jan 2014
Drug: DAS181-F02 formulation; DAS181-F04 formulation and 1 more · For: Influenza
Sites: San Diego, California
- DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)Pivotal-lookingStatus unknown
Ansun Biopharma, Inc.Industry
NCT04298060 · 280 participants (planned) · Start Jul 2020 · Primary completion Mar 2021
Drug: DAS181; Placebo · For: Influenza Infection; SAD-RV Infection and COVID-19
Sites: Shanghai, China
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT StudyPivotal-lookingRecruiting
Ansun Biopharma, Inc.Industry
NCT03808922 · 274 participants (planned) · Start May 23, 2019 · Primary completion Sep 1, 2028
Drug: DAS181; Placebo and 2 more · For: Lower Respiratory Tract Infection; Parainfluenza; Immunocompromised and 1 more
Sites: Duarte, California; Sacramento, California; Chicago, Illinois · 28 sites in all
- Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed InfluenzaPivotal-lookingCompleted
Ansun Biopharma, Inc.Industry
NCT01037205 · 264 participants · Start Dec 2009 · Primary completion Sep 2011
Drug: DAS181 dry powder, formulation F02; Respitose ML006 (DMV-Fonterra) · For: Influenza
Sites: Carmichael, California; Chula Vista, California; La Mesa, California · 42 sites in all
Qassim UniversityAcademic, hospital or other
NCT04460547 · 200 participants (planned) · Start Jul 25, 2020 · Primary completion Aug 15, 2020
Drug: Convalescent Plasma Transfusion; Hydroxychloroquine and 3 more · For: COVID-19
- A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental OxygenPivotal-lookingCompleted
Ansun Biopharma, Inc.Industry
NCT01644877 · 111 participants · Start Mar 2014 · Primary completion Dec 15, 2016
Drug: DAS181 dry powder, formulation F02; Lactose Placebo · For: Parainfluenza
Sites: Phoenix, Arizona; Duarte, California; Orange, California · 45 sites in all
Ansun Biopharma, Inc.Industry
NCT00876161 · 45 participants · Start May 18, 2009 · Primary completion Dec 2009
Drug: DAS181; Lactose · For: Healthy
Sites: Overland Park, Kansas
Ansun Biopharma, Inc.Industry
NCT00527865 · 36 participants (planned) · Start Oct 2007 · Primary completion Dec 2008
Drug: DAS181; Placebo · For: Influenza
Sites: Miramar, Florida
Ansun Biopharma, Inc.Industry
NCT01924793 · 23 participants · Start Aug 2013 · Primary completion May 2017
Drug: DAS181-F02 Dry Powder in Bulk; DAS181-F02 Nebulized Formulation Inhaled Dose · For: Parainfluenza
Sites: Duarte, California; Orange, California; Palo Alto, California · 23 sites in all
- Influenza Antiviral DAS181-F03Completed
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01173224 · 18 participants · Start Nov 2010 · Primary completion Jun 2011
Drug: Placebo; DAS181 · For: Influenza
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation.
El-Kafrawy SA, Othman NA, Zeyadi M, et al. · Front Cell Infect Microbiol 2026
- Sialidase fusion protein protects against influenza infection in a cigarette smoke-induced model of COPD.
Chang CY, Armstrong D, Knight JM, et al. · Mucosal Immunol 2025
- Inhibiting influenza virus transmission using a broadly acting neuraminidase that targets host sialic acids in the upper respiratory tract.
Ortigoza MB, Mobini CL, Rocha HL, et al. · mBio 2024
- Respiratory viral infections in the immunocompromised.
Ison MG · Curr Opin Pulm Med 2022
- DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study.
Chemaly RF, Marty FM, Wolfe CR, et al. · Clin Infect Dis 2021
- Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181.
Danziger-Isakov L, Khalil N, Divanovic A, et al. · Pediatr Infect Dis J 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.